• 4 ] However, such protection effectiveness may be lower for some reasons, especially when the vaccine strains are mismatched with circulating viruses. (biomedcentral.com)
  • The study authors acknowledge that these results may vary in years when circulating influenza strains differ significantly from those used in the vaccine. (medscape.com)
  • Next-generation vaccines that utilize T cells could potentially overcome the limitations of current influenza vaccines that rely on antibodies to provide narrow subtype-specific protection and are prone to antigenic mismatch with circulating strains. (mdpi.com)
  • This has provided hope for the design of a universal vaccine able to prime against diverse influenza virus strains and subtypes. (mdpi.com)
  • The post-marketing experience with AFLURIA (trivalent formulation) and AFLURIA QUADRIVALENT change to one or more new strains in each year's influenza vaccine. (who.int)
  • The principal changes include a) information about the influenza virus strains included in the trivalent vaccine for 1998-99, b) more detailed information about influenza-associated rates of hospitalization, and c) updated information on the possible relationship between Guillain-Barre syndrome and influenza vaccination. (cdc.gov)
  • The antigenic characteristics of circulating strains provide the basis for selecting the virus strains included in each year's vaccine. (cdc.gov)
  • However, due to antigenic drift in influenza viruses, vaccines need to be updated every year to protect against the circulating strains of the virus. (researchsquare.com)
  • Two hundred and five elderly subjects of Chinese ethnicity in Singapore (mean age 73.3 ± 5.3 years, 128 females and 77 males) were administered the recommended trivalent inactivated 2013-14 seasonal influenza vaccine (Vaxigrip™) containing A/H1N1, A/H3N2, and B strains. (frontiersin.org)
  • The vaccine efficacy for Flublok (trivalent formulation) was 44.8% against all strains, regardless of antigenic match, isolated from any subject with an ILI, not necessarily meeting the CDC-ILI criteria. (renalandurologynews.com)
  • the partners plan to exchange scientific information on avian influenza, share viral isolates, and may eventually manufacture human vaccines against avian viral strains. (nationalacademies.org)
  • The relatively simple methods developed by Burnet in Australia for culturing the virus on chick embryos, involving inoculation into the allantoic cavity, made it easy to obtain sufficient amounts of the virus strains for the vaccine. (medscape.com)
  • Thus, in 1942, 10,000 doses of the first bivalent vaccine containing the A/PR8 and B/Lee virus strains were administered in humans for testing. (medscape.com)
  • Influenza vaccine provides reasonable protection against immunized strains. (medscape.com)
  • 2 strains of influenza A and 2 of influenza B are included for the quadrivalent flu vaccines. (medscape.com)
  • Vaccines against seasonal influenza are reformulated annually to contain the most recently circulating strains. (medscape.com)
  • The vaccine viral strains recommended by the World Health Organization and the Centers for Disease Control and Prevention (CDC) for the 2023-2024 Northern Hemisphere influenza season differ from those from the previous influenza season. (medscape.com)
  • Hemagglutination inhibition (HAI) antibody titers to seasonal influenza strains are important surrogates for vaccine -elicited protection . (bvsalud.org)
  • Infections during the season were predominantly due to influenza A(H1N1)pdm09, with 90% of notifications being influenza A (56% A(H1N)1pdm09, 30% A(unsubtyped) and 4% A(H3N2)) and 10% being influenza B. The A(H1), A(H3) and B influenza viruses circulating during the 2010 season were antigenically similar to the respective 2010 vaccine strains. (health.gov.au)
  • Baseline and postvaccination serum samples were tested with hemagglutination inhibition (HI) assays against vaccine reference strains. (cdc.gov)
  • He developed protective levels of humoral antibodies (1:80 hemagglutination inhibition (HI) antibodies) against the three strains of the vaccine that evidently did not prevent respiratory infection. (bgu.ac.il)
  • The quadrivalent influenza vaccines contain an additional B strain, B/Brisbane/60/2008-like (B/Victoria lineage), in addition to the 3 viral strains listed above. (medscape.com)
  • Serological analyses demonstrated that homologous hemagglutination inhibition and microneutralization antibody titers were detectable in the ferrets after the first immunization with the AS03-adjuvanted vaccines that were further boosted by the second immunization. (nature.com)
  • In addition, heterologous antibody titers against older H7 subtype viruses of the North American lineage (H7N7, H7N3) and newer H7 subtype viruses of the Eurasian lineage (H7N9) were detected in the animals receiving the AS03-adjuvanted vaccines. (nature.com)
  • In addition, blood samples were collected for hemagglutination-inhibition titers 28 days after vaccination. (medscape.com)
  • The researchers found that the percentage of people with hemagglutination-inhibition titers 1:40 (the cut-off for seroprotection) or higher after vaccination was much higher in the high-dose vaccine group when compared with the standard-dose vaccine group. (medscape.com)
  • Administration of QIV with the two adjuvants, individually or combined, resulted in enhanced HA-specific serum ELISA IgG titers, serum hemagglutination inhibition (HAI) titers and splenic T cell responses as examined by IFN-γ and IL-4 enzyme-linked immunosorbent spot (ELISPOT) assays, 4-weeks post-prime and post-boost vaccination in BALB/c mice. (researchsquare.com)
  • Moreover, enhanced IgG2a titers correlate with antibody-mediated cellular cytotoxicity (ADCC) that targets both the highly conserved H1 hemagglutination (HA) stalk domain and N1 neuraminidase (NA). (researchsquare.com)
  • Additionally, vaccine-induced neutralizing antibody titers diminish over time, thereby affecting the extent of protection against infection during an entire influenza season and the subsequent seasons. (researchsquare.com)
  • Hemagglutination inhibition (HI) geometric mean titers (GMTs) were determined for the two vaccine groups for each vaccine antigen. (renalandurologynews.com)
  • In a randomized, phase 3, multicenter study , the experimental vaccine elicited high hemagglutination inhibition titers in patients. (medscape.com)
  • Infants born to mothers with low levels of antibody to measles (hemagglutination-inhibition antibody titers less than 1:40) were significantly more likely to have had natural measles (P less than 0.01) or to have seroconversion after vaccination (P less than 0.001) at 6 to 10 months of age than were infants born to mothers with higher of age than were infants born to mothers with higher titers. (unboundmedicine.com)
  • We report on a qualified and adaptable influenza serology method and analysis strategy to measure quantifiable HAI titers to define correlates of vaccine mediated protection in human clinical trials. (bvsalud.org)
  • Geometric mean titers (GMT), geometric mean fold rise (GMFR), seroconversion, and seroprotection (HI titer 40) were used to assess response to vaccine. (cdc.gov)
  • To provide further insight into these glycan attachments and their potential clinical relevance, the classic hemagglutination (HA) assay was applied using spike protein from the Wuhan, Alpha, Delta and Omicron B.1.1.529 lineages of SARS-CoV-2 mixed with human RBCs. (biorxiv.org)
  • The hemagglutination inhibition assay was used to measure antibody levels. (biomedcentral.com)
  • These first clinical trials demonstrated a good serological response to both influenza A and B. After two doses, there was an eight- to ninefold increase in antibody titer, measured by the hemagglutination inhibition assay. (medscape.com)
  • 158 (52.6%) tested positive for influenza A(H1N1) 2009 via hemagglutination inhibition assay using a ≥ 1:40 dilution cut-off. (biomedcentral.com)
  • 54.4% of those who tested positive for influenza A(H1N1) 2009 using the ≥ 1:40 dilution cut-off on the hemagglutination inhibition assay in this study population did not report experiencing symptoms during the pandemic meeting the May 2010 CDC definition of influenza-like illness. (biomedcentral.com)
  • GlaxoSmithKline (GSK) today announced results from its first clinical trial assessing use of its pandemic (H1N1) adjuvanted vaccine. (gsk.com)
  • The trial, which is taking place in Germany, involves 130 healthy volunteers aged 18 to 60 years old, and has been designed to evaluate the tolerability and immunogenicity of GSK's split-virus pandemic (H1N1) adjuvanted vaccine in comparison with an unadjuvanted test study formulation. (gsk.com)
  • GSK is conducting a further 15 studies in over 9000 subjects including healthy adults, the elderly and children (including infants) across Europe, Canada and the US to evaluate its pandemic (H1N1) adjuvanted vaccine. (gsk.com)
  • Furthermore, of those individuals who reported that they had received the H1N1 vaccine, 16% did not test positive. (biomedcentral.com)
  • 16% of those who reported receiving the H1N1 vaccine did not test positive by HAI. (biomedcentral.com)
  • We also found that vaccination coverage for H1N1 vaccine was poor among Blacks and Latinos, despite the fact that vaccine was readily available at no cost. (biomedcentral.com)
  • Background: Recent observational studies in the United States indicated live attenuated influenza vaccine (LAIV) was less effective in children against clinical influenza infection caused by A(H1N1)pdm09 relative to inactivated influenza vaccine (IIV). (cdc.gov)
  • LAIV receipt was the only factor associated with A(H1N1)pdm09 vaccine failure in the age-adjusted multivariable model (odds ratio 4.5, 95% CI 1.1-18.2). (cdc.gov)
  • One of the most effective prevention measures against YF is vaccination with the live, attenuated YF 17D substrain virus vaccine. (cdc.gov)
  • Therefore, if 10 or more years have elapsed since the last vaccination, people planning travel to a country with a YF vaccination entry requirement need to receive a booster dose of the vaccine. (cdc.gov)
  • This conclusion was based on a systematic review of published studies on the duration of immunity following a single dose of YF vaccine, and on data that suggest vaccine failures are extremely rare and do not increase in frequency with time since vaccination [Gotuzzo 2013]. (cdc.gov)
  • Vaccination history, age, health condition, and frequency of colds were important factors affecting the seroconversion rate of the influenza vaccine in human. (biomedcentral.com)
  • There is a need for developing optimized vaccination strategies for vulnerable groups to improve the efficacy of influenza vaccines in human. (biomedcentral.com)
  • The results may provide supporting data for identifying influenza vaccination low responders and optimizing the vaccination strategies, thereby improving the effectiveness of the influenza vaccine in human. (biomedcentral.com)
  • Statistical associations were evaluated between frailty status and pre- and post-vaccination antibody titres in sera measured by Hemagglutination inhibition (HAI) and microneutralization (MN) assays. (frontiersin.org)
  • Post-vaccination immunogenicity was evaluated on sera obtained 28 days after administration of a single dose of study vaccine. (renalandurologynews.com)
  • Influenza vaccination should not be delayed to procure a specific vaccine preparation if an appropriate one is already available. (medscape.com)
  • A sudden increase in the incidence of childhood narcolepsy was observed after vaccination with AS03-adjuvanted Pandemrix influenza vaccine in Finland at the beginning of 2010. (plos.org)
  • The lowest rate of vaccine failure compatible with acceptably low rates of natural infections could be achieved by vaccination after eight months of age. (unboundmedicine.com)
  • 1 or 2 doses depends on vaccination history as per Advisory Committee on Immunization Practices annual recommendations on prevention and control of influenza with vaccines. (nih.gov)
  • Vaccination is also recommended for persons at increased risk of severe vaccine-preventable disease. (smw.ch)
  • Title: Evaluation of the effects of age, prior exposure and previous vaccination on the B cell response to inactivated influenza vaccine in healthy adults and children. (rochester.edu)
  • Description of demographic and clinical characteristics and immune response to vaccination among subjects who develop symptomatic influenza (Vaccine Failures) and among subjects who do not. (rochester.edu)
  • and 5) the assessment of vaccine supply, timing of influenza vaccination, and prioritization of inactivated vaccine in shortage situations. (cdc.gov)
  • This reluctance is based on sporadic case reports on the onset or exacerbation of the disease following vaccination with influenza, tetanus, hepatitis, and other vaccines. (bmj.com)
  • H3N2v-specific plasmablasts were determined by ELISpot 8 days after each vaccine dose and H3N2v specific CD4+ T cells were quantified by intracellular cytokine and CD154 (CD40 ligand) staining before vaccination, 8 and 21 days after each vaccine dose. (emmes.com)
  • These results suggested that the CPD of the surface glycoprotein genes of the LS strain does not sufficiently attenuate the virus for in ovo vaccination, and other virus attenuation approaches are needed to develop a safe in ovo NDV vaccine. (usda.gov)
  • Furthermore, vaccination is just one of the preventive measures aimed at protecting the vaccine recipients against certain diseases. (drfarrahmd.com)
  • Therefore, the WHO's proposal to eliminate cervical cancer through HPV vaccination is unscientific and sounds like a marketing campaign for the vaccine products. (drfarrahmd.com)
  • [ 8 ] With an inactivated virus vaccine, the amount of antigen required to induce immunity is much greater than that for a live-attenuated virus vaccine, because unlike the live-attenuated virus, the inactivated virus does not replicate in the recipient. (medscape.com)
  • Conventional vaccines-live attenuated or inactivated-have proved to be beneficial against a number of infectious diseases in the past. (canada.ca)
  • From the graph below, we can see that among children aged 5 to 9, in terms of T-cell response stimulation, inactivated flu vaccines are less effective than live attenuated influenza vaccines (LAIVs) ( pdf ). (drfarrahmd.com)
  • Influenza vaccine is also available as a nasal spray (FluMist) that contains live, attenuated influenza virus (LAIV). (medscape.com)
  • When asked to comment on these findings, Nasia Safdar, MD, from the University of Wisconsin School of Medicine and Public Health in Madison, said: "This is the first major trial to show that a high-dose influenza vaccine actually reduces influenza in older adults, not just improved antibody responses. (medscape.com)
  • Human infections with avian H7N9 subtype influenza viruses are a major public health concern and vaccines against H7N9 are urgently needed for pandemic preparedness. (nature.com)
  • Currently, there is no licensed H7N9 vaccine available and people infected with H7N9 viruses are only treated therapeutically with neuraminidase inhibitors. (nature.com)
  • HA and HAI apply the process of hemagglutination, in which sialic acid receptors on the surface of red blood cells (RBCs) bind to the hemagglutinin glycoprotein found on the surface of influenza virus (and several other viruses) and create a network, or lattice structure, of interconnected RBCs and virus particles. (wikipedia.org)
  • Hemagglutination is observed in the presence of staphylococci, vibrios, and other bacterial species, similar to the mechanism viruses use to cause agglutination of erythrocytes. (wikipedia.org)
  • Because of the close antigenic relationships among many extent the 17-D YFV vaccine--modify subsequent WNV viruses in this genus, Flavivirus infections are difficult to dif- infection and protect the animals from fatal encephalitis. (cdc.gov)
  • Antigenic changes also necessitate frequent updating of influenza vaccine components to ensure that the vaccine is matched to circulating viruses. (cdc.gov)
  • 2 ] The risk of seeking treatment will decrease by 40-60% if influenza vaccine viruses match circulating viruses. (biomedcentral.com)
  • In this role, CDC conducts surveillance of seasonal flu viruses circulating in people to make informed decisions on the selection of viruses for use in creating seasonal flu vaccines. (cdc.gov)
  • As part of CDC's role as a WHO Collaborating Centre for Influenza, CDC also receives zoonotic viruses of public health concern that CDC characterizes and uses to create candidate vaccine viruses (CVVs) that can be used to produce vaccines against viruses with pandemic potential. (cdc.gov)
  • The majority of SAEs occurred after c adverse events listed below reflect experience in both children and adults and include those a causal relation of GBS with subsequent vaccines prepared from other influenza viruses is unclear. (who.int)
  • This virus was named Influenza B and the inactivated influenza vaccine had to be bivalent to provide protection against both types of influenza viruses (Figure 1). (medscape.com)
  • Evolution of influenza viruses and corresponding evolution of influenza vaccines. (medscape.com)
  • A goal of many research works is to produce universal vaccines that can induce protective immunity to influenza A viruses of various subtypes. (biomedcentral.com)
  • Historically, influenza vaccine has had 50-60% efficacy against infection with influenza A viruses and 70% efficacy against influenza B viruses. (medscape.com)
  • Influenza vaccine component recommendations are based on numerous factors, including global influenza virologic and epidemiologic surveillance, genetic and antigenic characterization, antiviral susceptibility, and the availability of candidate vaccine viruses for production. (medscape.com)
  • As these viruses are largely uncharacterized before an outbreak occurs, time becomes a crucial factor for effective vaccine development. (canada.ca)
  • Biological assays showed that the codon deoptimized viruses maintained similar hemagglutination activity in embryonated eggs as the parental rLS virus. (usda.gov)
  • Currently, the most commonly used production method of influenza vaccines is the egg-based approach, in which flu viruses grow and replicate themselves. (drfarrahmd.com)
  • Measurement of the magnitude and specificity of the serum antibody responses by hemagglutination (HAI), microneutralization (MN), genome fragment phage display (GFPD), surface plasmon resonance (SPR), and Hemagglutinin Array assays at day 7 and 28, overall and stratified by age group, vaccine history, and baseline serum antibody level. (rochester.edu)
  • 29 , 37 Most reference laboratories have developed in-house MVEV serological tests that can detect total antibody by haemagglutination inhibition, IgG by immunofluorescence assays (IFA) or enzyme immunoassays (EIA), and IgM by IFA or EIA. (mja.com.au)
  • In addition, microscopic examination post-challenge showed animals immunized with the AS03-adjuvanted vaccines had the least signs of lung injury and inflammation, consistent with the greater relative efficacy of the adjuvanted vaccines. (nature.com)
  • however, based on data from previous studies that suggest 50% efficacy of standard-dose vaccine in older adults, they estimate the absolute efficacy of the high-dose vaccine at 62%, "a level of protection similar to that seen with standard-dose vaccines in younger adults. (medscape.com)
  • Safety, Immunogenicity, Efficacy and Effectiveness of Inactivated Influenza Vaccines in Healthy Pregnant Women and Children Under 5 Years: An Evidence-Based Clinical Review. (europa.eu)
  • This optimism is built on recently published studies demonstrating the efficacy of mRNA vaccines in combatting several types of cancer and infectious pathogens where conventional vaccine platforms may fail to induce protective immune responses. (researchgate.net)
  • Attack rates and vaccine efficacy (VE), defined as the reduction in the influenza rate for Flublok relative to placebo, were calculated for the total vaccinated cohort (n=4648). (renalandurologynews.com)
  • the vaccine had 47% efficacy against the predominant influenza A H3N2 subtype and 67% efficacy against influenza B virus infections. (medscape.com)
  • through antigenic drift is the virologic basis for seasonal epidemics and the reason for the usual appeared related to the study vaccines. (who.int)
  • Therefore, elderly individuals above 65 years of age are considered to be at a greater risk of influenza infection and its complications, and it is hence recommended that they receive an annual administration of seasonal influenza vaccine ( 3 ). (frontiersin.org)
  • This study includes 3 parts: Parts A, B, and C. The purpose of this study is to evaluate the immunogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults. (clinicaltrials.gov)
  • Participants will receive a single dose of licensed quadrivalent inactivated seasonal influenza vaccine by IM injection on Day 1. (clinicaltrials.gov)
  • To evaluate the relationship between first influenza A virus exposure (inferred by age), vaccine history, and baseline serum antibody and Memory B cell (MBC) specificity, and the magnitude and breadth of the subsequent B cell response to seasonal influenza vaccine in healthy adults and children. (rochester.edu)
  • As a result, the approval of the vaccine significantly increased GSK's potential production capacity for both seasonal and pandemic influenza vaccines. (clinicaltrialsarena.com)
  • It gives a full rundown of the current NP-based vaccines, their potential as adjuvants, and the ways they can be delivered to cells. (researchgate.net)
  • The goal of this study was to explore a RIG-I agonist (SDI-nanogel) and a TLR7/8 agonist (Imidazoquinoline (IMDQ)‐PEG‐Chol) as adjuvants, when co-administered with a licensed quadrivalent inactivated influenza vaccine (QIV), and to determine the role of these adjuvants in directing helper T (Th) cell responses for their role in the immunoglobulin (Ig) class switching. (researchsquare.com)
  • This study details the benefit of adjuvants that target multiple innate immune receptors to shape the host vaccine response. (researchsquare.com)
  • Adjuvants such as AS03 improve vaccine immunogenicity, but this mechanism is poorly understood. (nature.com)
  • Adjuvants can enhance vaccine immunogenicity, allowing a reduction in the quantity of antigen per dose and a consequent increase in the number of doses that can be manufactured in a given time-period. (nature.com)
  • Despite the success of these adjuvants, the details of their mode of action in the context of influenza vaccine are still poorly understood. (nature.com)
  • In this review we use influenza vaccine as a model in a discussion of the different mechanisms of action of the available adjuvants. (smw.ch)
  • In addition, we will appraise new approaches using "vaccine-omics" to discover novel types of adjuvants. (smw.ch)
  • This study aimed to explore factors related to the immune response to influenza vaccines. (biomedcentral.com)
  • The Chi-square test, multivariable logistic regression analysis, and sum-rank test were used to analyze the factors associated with influenza vaccine immune response. (biomedcentral.com)
  • The mRNA vaccines can encode multiple antigens, strengthening the immune response against pathogens and enabling the targeting of multiple microbial variants [19] . (researchgate.net)
  • Therefore, there is an urgent need for a better cost-effective influenza vaccine which can induce antigenically broader and long-lasting immune response. (researchsquare.com)
  • The results demonstrate that after one dose the candidate vaccine can provide a strong immune response which exceeds the immunogenicity criteria as defined by international licensing authorities for a pandemic influenza vaccine. (gsk.com)
  • Vaccines offer the potential to prime a pathogen-specific immune response and subsequently reduce disease burden. (smw.ch)
  • The vaccine-induced immune response is influenced by: (i.) vaccine factors i.e., type and composition of the antigen(s), (ii. (smw.ch)
  • Evaluate factors related to failure of vaccine to provide protection against symptomatic influenza and the immune response to infection in vaccinated individuals by prospective surveillance of the vaccine cohort. (rochester.edu)
  • The preliminary data on the safety of the vaccine and its immune response in adult patients were also studied during the trials. (clinicaltrialsarena.com)
  • The Strategic Advisory Group of Experts on Immunization (SAGE), the principal advisory group to the World Health Organization (WHO) for vaccines and immunization, concluded in April 2013 that a single dose of YF vaccine is sufficient to confer sustained immunity and lifelong protection against YF disease, and a booster dose of the vaccine is not needed [WHO 2013]. (cdc.gov)
  • Evidence from multiple studies demonstrates that YF vaccine immunity persists for many decades and might provide life-long protection" [CDC 2010]. (cdc.gov)
  • Heterosubtypic immunity (HSI) is the basis of creating universal influenza vaccines. (biomedcentral.com)
  • A vaccine (or vaccines) against SARS-CoV-2 would help develop community immunity against the virus and thus prevent the spread and recurrence of the disease at the population level. (canada.ca)
  • While the rapid development of COVID-19 vaccines has been a scientific triumph, the need remains for a globally available vaccine that provides longer-lasting immunity against present and future SARS-CoV-2 variants of concern (VOCs). (stanford.edu)
  • H3N2 influenza hemagglutination inhibition method qualification with data driven statistical methods for human clinical trials. (bvsalud.org)
  • Influenza A (H3N2) continues to be a predominant circulating subtype in most countries in Europe and North America since 1968 and is thus a focus of influenza vaccine research . (bvsalud.org)
  • Baseline Levels of Influenza-Specific B Cells and T Cell Responses Modulate Human Immune Responses to Swine Variant Influenza A/H3N2 Vaccine. (emmes.com)
  • In this study, two H7N9 split virion vaccines with or without AS03 adjuvant were tested in the naive ferret model. (nature.com)
  • 82 rheumatoid patients and 30 healthy controls were vaccinated with a split-virion inactivated vaccine containing 15 μg haemagglutinin (HA) per dose of each of B/Hong Kong/330/2001 (HK), A/Panama/2007/99 (PAN), and A/New Caledonian/20/99 (NC). (bmj.com)
  • FluLaval is an injectable split-virion influenza virus vaccine used as active immunisation for adults against influenza disease. (clinicaltrialsarena.com)
  • FluLaval is an injectable split-virion influenza virus vaccine used as active immunisation for adults against influenza disease caused by influenza virus subtypes A and B. The vaccine is propagated in the allantoic cavity of embryonated hens' eggs. (clinicaltrialsarena.com)
  • We enrolled volunteers who were: (1) Han Chinese, (2) and had not already received the northern hemisphere formulation of influenza vaccine for the corresponding year. (biomedcentral.com)
  • An age-appropriate formulation of vaccine should be used. (medscape.com)
  • The antigen content of the adjuvanted vaccine is comparable to the expected final formulation of the adjuvanted vaccine of 3.75ug. (gsk.com)
  • They are then isolated, purified, and inactivated, before being added to the formulation to produce vaccines. (drfarrahmd.com)
  • The ACIP Japanese Encephalitis Vaccine Work Group was reformed to include YF vaccine in October 2013 to discuss the need for booster doses of YF vaccine. (cdc.gov)
  • The primary policy question was "Should booster doses of YF vaccine every 10 years continue to be recommended for healthy travelers and laboratory workers? (cdc.gov)
  • Each individual was given either two doses of vaccine or placebo 3 weeks apart on day 1 and day 22. (medscape.com)
  • To enable global accessibility, we generated a cell line that can enable production of thousands of vaccine doses per liter of cell culture and show that DCFHP-alum maintains potency for at least 14 days at temperatures exceeding standard room temperature. (stanford.edu)
  • Twenty-five subjects, enrolled in an investigational influenza A/H3N2v vaccine study, who received two doses of vaccine 21 days apart, were included in a sub-study of cellular immune responses. (emmes.com)
  • GSK now plans to bring more than 30m doses of flu vaccine to the US market for the current influenza season. (clinicaltrialsarena.com)
  • 5 ] The immunogenicity of the vaccine is also one of the most important factors influencing vaccine effectiveness. (biomedcentral.com)
  • Likewise, the effect of commonly used drugs in rheumatoid arthritis, such as methotrexate and TNFα blockers, on the immunogenicity of the vaccine has not been well established. (bmj.com)
  • AFLURIA is an inactivated influenza virus vaccine indicated for active immunization of persons ages 6 months and older against influenza disease caused by influenza virus subtypes A and type B present in the vaccine. (drugs.com)
  • AFLURIA is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza virus subtypes A and type B present in the vaccine. (nih.gov)
  • Vaccine-induced antibody and T cell responses correlated with protection against lethal influenza virus infection. (researchsquare.com)
  • Moreover, antibody responses induced by influenza virus vaccines are usually short-lived and less cross-reactive against antigenically drifted virus variants than those induced by a natural influenza virus infection 1 . (researchsquare.com)
  • No statistically significant differences were observed between the frailty groups in vaccine-induced modulation of leukocyte populations, cytokine responses, and gene expression profiles of peripheral blood mononuclear cells (PBMCs). (frontiersin.org)
  • First, the adjuvant stimulates increased activation of naïve B cells, thus reducing immune interference with previous vaccine responses. (nature.com)
  • Chiu C, Wrammert J, Li GM, McCausland M, Wilson PC, Ahmed R. Cross-reactive humoral responses to influenza and their implications for a universal vaccine. (smw.ch)
  • The cellular immune responses elicited by an investigational vaccine against an emergent variant of influenza (H3N2v) are not fully understood. (emmes.com)
  • During the 2013-2014 influenza season, we conducted an observational study among children aged 5-17 years to compare serologic responses to LAIV and IIV and explore factors associated with vaccine failure. (cdc.gov)
  • When implementing flu vaccines, the more responses from T cells and B cells, the better. (drfarrahmd.com)
  • Influenza vaccine effectiveness could be improved by combination with an adjuvant with the potential to enhance the host-vaccine response both quantitatively and qualitatively. (researchsquare.com)
  • Second, the adjuvant is able to increase the adaptability of the recalled cells to give improved specificity to the new vaccine antigen. (nature.com)
  • Understanding the mode of action of the adjuvant can be helped by studying the properties of the plasma cells produced in response to the vaccine. (nature.com)
  • Here, we describe DCFHP, a ferritin-based, protein-nanoparticle vaccine candidate that, when formulated with aluminum hydroxide as the sole adjuvant (DCFHP-alum), elicits potent and durable neutralizing antisera in non-human primates against known VOCs, including Omicron BQ.1, as well as against SARS-CoV-1. (stanford.edu)
  • 13.2 reactions following administration of the vaccine. (who.int)
  • Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of the vaccine. (nih.gov)
  • Administration of CSL's 2010 Southern Hemisphere influenza vaccine has been associated with increased postmarketing reports of fever and febrile seizures in children predominantly below the age of 5 years as compared to previous years. (drugs.com)
  • In the Northern Hemisphere, all persons aged 6 months or older should receive influenza vaccine annually, by the end of October, if possible. (medscape.com)
  • High-dose influenza vaccine provides better protection against influenza when compared with standard-dose vaccine among persons aged 65 years and older, according to results from a new study published in the August 14 issue of the New England Journal of Medicine . (medscape.com)
  • Researchers from Sanofi Pasteur, which funded the study, conducted a phase 3b-4 double-blind, active-controlled trial in which they compared a high-dose, trivalent, inactivated influenza vaccine (IIV3-HD) with standard-dose, trivalent, inactivated influenza vaccine (IIV3-SD) in 31,989 people aged 65 years or older. (medscape.com)
  • Given these study findings however, "our evidence base is now much greater in recommending [high-dose vaccine] to patients," Dr. Safdar concluded. (medscape.com)
  • Cite this: Influenza: High-Dose Vaccine Decreases Flu in Older Adults - Medscape - Aug 14, 2014. (medscape.com)
  • Participants were randomly assigned 1:1 to receive a single dose of Flublok Quadrivalent or a US-licensed quadrivalent inactivated influenza vaccine (Comparator, Fluarix Quadrivalent). (renalandurologynews.com)
  • Results of the adjuvanted vaccine demonstrated that hemagglutination-inhibition titres exceeded the regulatory threshold, with a 1:40 seroconversion in more than 98% of subjects receiving the first dose. (gsk.com)
  • This trial provides encouraging data on the potential use of a single dose of our pandemic vaccine. (gsk.com)
  • Many current nonadjuvanted vaccines are poorly effective in the elderly and immunocompromised populations, resulting in nonprotective postvaccine antibody titres, which serve as surrogate markers for protection. (smw.ch)
  • They furthermore suggest therapeutic options using competitive glycan-binding agents such as IVM and may help elucidate rare serious adverse effects (AEs) associated with COVID-19 mRNA vaccines which use spike protein as the generated antigen. (biorxiv.org)
  • Messenger RNA (mRNA) vaccines represent a relatively new vaccine class showing great promise for the future. (researchgate.net)
  • This review summarizes the most important developments in mRNA vaccines from the past few years and discusses the challenges and future directions for the field. (researchgate.net)
  • For example, 'Two mRNA vaccines developed by Pfizer-BioNTech and Moderna are effective against the coronavirus. (researchgate.net)
  • Influenza virus vaccine generated a good humoral response in rheumatoid patients, although lower than in healthy controls. (bmj.com)
  • This bivalent vaccine contained 0.5 ml of virus concentrated from 5 ml of allantoic fluid containing influenza A and the same amount of influenza B. One half of the influenza A allantoic fluid contained the A/PR8 strain and the other half contained the Weiss strain, a strain that had been isolated more recently and that was slightly different from A/PR8. (medscape.com)
  • Time is necessary to produce a vaccine that is antigenically matched to a pandemic strain. (biomedcentral.com)
  • In this study, mice were vaccinated with recombinant virus vaccine (rL H5), in which the hemagglutinin (HA) gene of influenza A/H5N1 virus was inserted into the LaSota Newcastle disease virus (NDV) vaccine strain. (biomedcentral.com)
  • Recent AIV isolates (2002-2006) show significant molecular drifts when compared with the H5N2 vaccine-strain or other field isolates (1994-2000). (biomedcentral.com)
  • The vaccine strain officially authorized, as seed for commercial vaccine production is the A/Ck/México/CPA-232/94 (H5N2), isolated in 1994 [ 3 ]. (biomedcentral.com)
  • We compared HA gene sequences from AIVs isolated between 1994 and 2000 [ 3 ], more recent isolates (2002 to 2006) from vaccinated birds showing clinical manifestations of avian influenza, and the A/Chicken/Hidalgo/232/94 vaccine strain. (biomedcentral.com)
  • Results: LAIV and IIV recipients were similar with respect to demographics and baseline GMT for each vaccine strain. (cdc.gov)
  • Adjuvanted influenza vaccines can overcome the poor antibody response of conventional non-adjuvanted vaccines in the elderly. (nih.gov)
  • The analysis was based on the presence or absence of antibody response against non-structural protein 1 (NS1) from H1N1pdm09 virus, which was not a component of Pandemrix vaccine. (plos.org)
  • Nonetheless, the protecting hemagglutination inhibition (HAI) antibody response to influenza vaccine is affected by many components, amongst which single nucleotide polymorphisms (SNPs) within. (forsker.net)
  • 20.3%, 24.1%, and 20.0% of adults 65 years who received AFLURIA QUADRIVALENT, TIV-1, and Because postmarketing reporting of adverse events is voluntary and from a population of uncertain influenza vaccine have not been correlated with protection from influenza virus. (who.int)
  • A newly developed influenza vaccine against the H5N1 subunit of the avian influenza virus, which has pandemic potential, has been shown to be highly immunogenic in younger and older adults . (medscape.com)
  • We can see that although the same type of flu vaccines were administered, in terms of T cell response, the vaccines are more effective in children aged 5 to 9 years than in adults. (drfarrahmd.com)
  • Influenza vaccine immunology. (smw.ch)
  • and second, will the vaccine(s) be protective enough to completely prevent the further spread of the virus. (canada.ca)
  • got substantial antibody increases without reported disease, suggesting how the vaccine was protective however primed for anamnestic reactions to RSV. (health-ground.com)
  • Response was greater in young vaccine recipients. (medscape.com)
  • One comparator-controlled trial demonstrated higher rates of fever in recipients of AFLURIA as compared to a trivalent inactivated influenza vaccine control. (nih.gov)
  • RT-PCR confirmed influenza (vaccine failure) occurred in 8 (13%) of 62 LAIV recipients and 3 (3%) of 99 IIV recipients (p = .02). (cdc.gov)
  • Although cost-effective, this method is prone to mutations, which can lower the vaccines' effectiveness and cause potential problems, such as weakening the vaccine recipients' immune system. (drfarrahmd.com)
  • In addition, different vaccine platforms also have different effects on vaccine recipients. (drfarrahmd.com)
  • We evaluated the immunogenicity, safety and clinical effectiveness of an MF59(®)-adjuvanted trivalent influenza vaccine (aTIV) compared with a non-adjuvanted vaccine (TIV) in subjects ≥65 years old, with or without co-morbidities. (nih.gov)
  • Multilevel Implementation Strategies for Adolescent Human Papillomavirus Vaccine Uptake: A Cluster Randomized Clinical Trial. (mayo.edu)
  • The potential advantages of the nucleic acid vaccines over conventional vaccines are presented, and the nucleic acid vaccines currently in development against viral infections and the challenges these vaccines face entering clinical trial are discussed. (canada.ca)
  • Our next step is to complete this trial, as well as 15 other studies in our clinical development programme for the vaccine. (gsk.com)
  • Phase III clinical trials on the FluLaval vaccine in the US were initiated in September 2006. (clinicaltrialsarena.com)
  • This report updates the 2004 recommendations by the Advisory Committee on Immunization Practices (ACIP) regarding the use of influenza vaccine and antiviral agents (CDC. (cdc.gov)
  • This case emphasizes the importance of an improved vaccine that would stimulate a better immunologic response, especially in immunocompromised patients. (bgu.ac.il)